Efficacy and safety of tegoprazan combined with itopride in treatment of reflux esophagitis

Zhao Wen-tao; Sun Han; Jiao Xiao-hong

doi:10.3969/j.issn.1672-8157.2025.01.009

Abstract：Objective To investigate the efficacy and safety of tegoprazan combined with itopride in the treatment of reflux esophagitis(RE).Methods A total of 94 RE patients admitted to 417 Hospital of Nuclear Industry from May 2022 to May 2024 were selected and divided into 2 groups using the random table method.The patients in the control group(n=47)were given oral ito-pride hydrochloride tablets and rabeprazole sodium enteric-coated tablets while those in the observation group(n=47)were given oral itopride and tegoprazan.All the patients in both groups were treated continuously for 8 weeks.The clinical efficacy,positive expression of epidermal growth factor receptor(EGFR)and adverse reactions were compared between the two groups.Results The total effec-tive rate and EGFR positive expression rate were significantly higher in the observation group than in the control(97.87%(46/47)vs 82.98%(39/47),82.98%(39/47)vs 61.70%(29/47))(χ2=6.021,5.317,both P<0.05).After treatment,the levels of serum gastrin-17(G-17)and pepsinogenⅡ(PGⅡ)in the observation group were(106.26±8.33)pg·mL-1 and(15.32±1.27)μg·L-1,which were lower than those of(115.58±9.17)pg·mL-1 and(21.71±2.35)μg·L-1 in the control(t=5.528,17.579,both P<0.05).PepsinogenⅠ(PG-Ⅰ)was(131.68±10.71)μg·L-1 in the observation group,which was higher than that of(122.59±9.46)μg·L-1 in the control(t=4.675,P<0.05).The total incidence of adverse reactions showed no significant difference between the two groups(10.64%,5/47 vs 14.89%,7/47)(χ2=0.382,P>0.05).Conclusion Tegoprazan combined with itopride has significant efficacy in the treatment of RE patients since it can improve the level of gastrointestinal hormones.Meanwhile,it is of high safety.